HBM Holdings Limited (HKG:2142)

Market Cap	11.62B
Revenue (ttm)	908.35M
Net Income (ttm)	573.61M
Shares Out	869.43M
EPS (ttm)	0.72
PE Ratio	18.47
Forward PE	19.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,509,719
Average Volume	4,218,813
Open	13.54
Previous Close	13.36
Day's Range	13.10 - 13.54
52-Week Range	1.12 - 17.98
Beta	1.85
RSI	48.25
Earnings Date	Nov 27, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD